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Abstract
Biological sex is an independent risk factor of cancer. Men are three to five times 
more likely than women to develop bladder cancer even when known risk factors 
are taken into consideration. Development of sex in mammals is often viewed as 
a two-step process. The first step is sex determination, of which the XX and XY 
sex chromosome complements trigger gonad differentiation to form the ovary and 
testis, respectively. After that, sex hormones secreted by gonads initiate sexually 
dimorphic differentiation of nongonadal tissues. However, this model has been 
challenged by recent findings revealing an independent contribution of sex chro-
mosomes to sexual dimorphism. In this chapter, we discuss how the sex chromo-
somes and sex hormones together cause gender disparities in bladder cancer. We 
propose a concept of epigenetic sex – epigenetic differences between males and 
females – and suggest that the sex epigenome is a previously unknown biasing fac-
tor contributing to gender disparities in bladder cancer.
Keywords: Bladder Cancer, Gender Disparities, Sex Hormones, Sex Chromosomes, 
Sex Epigenome, KDM6A, PRC2, COMPASS
1. Introduction
Bladder cancer (BC) originates primarily from the urothelium – the inner lining 
of bladder lumen. Men are disproportionally affected by the disease. Males are 3–5 
times more likely than females to BC [1]. This difference persists even after adjust-
ing other known risk factors [2–5], suggesting that male sex is an independent risk 
factor of BC.
Typical males have one copy each of the X and Y chromosomes (XY) while females 
have two copies of the X chromosome (XX). For XY individuals, sex-determining 
region Y (SRY) gene on the Y chromosome triggers gonadal differentiation to form 
testes, which secrete androgens and promote male primary and secondary sex charac-
teristics. Females with XX chromosome complement have ovarian development and 
estrogen secretion leading to female primary and secondary sex characteristics [6].
Strong evidence exists that androgens acting through androgen receptor, pro-
mote bladder tumorigenesis [7]. Female gonadal hormones acting through estrogen 
receptors also influence BC risk albeit playing a minor role when compared to 
androgens [8]. While sex hormones clearly play important roles in gender dispari-
ties in BC, potential role of the sex chromosomes is not nearly as apparent. Because 
the sex chromosomes (i.e., XX vs. XY) are coupled with the gonadal hormones (e.g., 
estrogens vs. androgens), it is exceedingly difficult to ascertain independent effects 
of the sex chromosomes or the gonadal hormones [6]. Creative tools are needed 
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to overcome the challenges of studying sex differences in physiology and disease 
[9]. Here, we review how the sex hormones and chromosomes function together 
to cause gender disparities in BC and, furthermore, propose a novel concept of 
epigenome sex.
2. The impact of biological sex on bladder cancer development
2.1 The role of androgen
A retrospective study revealed that male patients who received α-reductase 
inhibitors before the diagnosis of BC had better survival and was positively cor-
related with duration of administration [10]. Similarly, prostate cancer patients 
who received androgen deprivation therapy (ADT) had a lower incidence of BC 
compared with patients that did not [11]. Paradoxically, a majority of expression 
analyses of androgen receptor (AR) in BC patients showed a negative correlation 
between AR expression and the aggressiveness of BC [12–17]. Offering a possible 
explanation underlying this observation is our finding that reduced AR expres-
sion may lead to upregulation of cancer stem cell related genes such as CD44 [18]. 
Clearly the role of androgens and AR in BC is complex and likely in molecular and 
cellular context-dependent manner.
Animal models of BC support the role of androgens/AR in modulating blad-
der tumorigenesis. Male mice were much more vulnerable than female mice to BC 
induced by N-butyl-N-(4- hydroxybutyl) nitrosamine (BBN), a bladder-specific 
carcinogen [19]. This sex difference was blunted by castration. Similarly, Okajima 
and colleagues have observed male-biased responses to BBN-induced BC in rats. 
Moreover, administration of Diethylstilbestrol (DES), a nonsteroidal estrogen, sup-
pressed bladder carcinogenesis in male rats. In contrast, testosterone supplementation 
increased the incidence of BC in female rats [20]. Miyamoto et al. have also found that 
AR knockout (KO) mice, both males and females, were completely protected from 
BBN-induced BC [21]. Intriguingly, 25% AR KO male mice supplemented with dihy-
drotestosterone (DHT) had BC after BBN treatment, and 50% of castrated male mice 
still developed into BC [21]. These data suggest that androgens have AR-independent 
function in promoting BBN-induced BC, and AR may also function in an androgen-
independent manner. In addition, they showed that androgen deprivation or 
androgen/AR disruption blunted growth of AR-positive human BC cells both in vitro 
and in vivo [21]. The genetic evidence of oncogenic role of androgen/AR signaling 
in bladder carcinogenesis was further confirmed in the subsequent studies. Hsu 
and colleagues revealed that urothelium-specific conditional KO of AR reduced the 
risk of BBN-induced BC in male mice. They further showed that AR expression was 
inversely associated with the level of p53-PCNA-DNA damage pathway, implicating 
a possible downstream event of AR oncogenic signaling [22]. Johnson et al. showed 
that conditional overexpression of human AR in mouse urothelium was sufficient 
to promote BBN-induced BC in both sexes and the phenotype in males could be 
alleviated by castration [23]. Surprisingly, the study also suggested that AR did not 
function through known molecular pathways which have been previously implicated, 
including p53 [22], Wnt/β-catenin [24, 25], and CD24 [26–28]. Therefore, much more 
work is needed to define the precise role of AR in bladder tumorigenesis.
2.2 The role of estrogens and their receptors
Postmenopausal women had a higher risk of BC and early menopause 
enhanced this risk, suggesting that female sex hormones protect women from BC 
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development [29–31]. Classical estrogen receptors (ERs) include estrogen receptor 
α (ERα) and estrogen receptor β (ERβ) [32]. Clinically, inconsistent results existed 
between the expression of ERα and ERβ and the grades and stages of BC patients 
although more reports supported that expression of ERα favors a better while 
ERβ is associated with a worse prognosis [14, 32–38]. Experimentally, both whole 
body ERα KO or urothelium-specific ERα KO increased the incidence of BBN-
induced BC in female mice. Disruption of ERα decreased the expression of Inositol 
polyphosphate-4-phosphatase, type II (INPP4B), resulting in a higher activation of 
AKT [39]. On the contrary, whole body deletion of ERβ impeded BBN-induced BC 
in female mice [40]. Moreover, knockdown (KD) of ERβ suppressed transformation 
of normal bladder cells and growth of BC cells partly through reducing expression 
of mini-chromosome maintenance complex component 5 (MCM5) because rein-
troduction of MCM5 into BC cells blunted ERβ KD phenotype [40]. Interestingly, 
tamoxifen treatment conferred a chemoprevention in female mice against BBN-
induced BC [41]. Since tamoxifen is a selective estrogen-receptor modulator with 
mixed estrogenic and antiestrogenic activity depending on targeted tissues, it 
would be interesting to see which ERs, ERα or ERβ, is activated or inhibited and 
whether any of these receptors plays a more dominant role in the BBN-induced 
bladder carcinogenesis.
2.3 The role of sex chromosomes in driving gender disparities
A potential role of the sex chromosomes in gender disparities in BC was impli-
cated initially by cancer epidemiological findings of Turner and Klinefelter patients. 
Turner syndrome is a genetic disorder of female X0 patients who lost one copy of 
the X chromosome. Conversely, Klinefelter syndrome has two or more copies of 
the X chromosome among the affected male patients. Turner patients displayed 
an increased risk of BC [42]; and Klinefelter patients had an overall reduced rate 
of solid tumors [43]. These observations suggest that an extra copy of X chromo-
some is tightly associated with low BC risk in both sexes. However, because the sex 
chromosomes are tightly coupled with their respective sex/gonadal hormones, the 
confounding effect of sex chromosomes cannot be excluded. As a result, the sex 
hormone–independent roles of the sex chromosomes have largely been overlooked.
To overcome the aforementioned challenges of studying independent roles 
of the sex-biasing factors, De Vries et al. developed “four-core genotype (FCG)” 
mouse model to uncouple the link between the sex chromosomes and their cor-
responding gonadal types [44]. In this model, Sry gene is “transferred” from the Y 
chromosome to an autosome. As a result, the FCG mouse model has four instead 
of two sex types: 1. XY male with testes (XYM); 2. XX male with testes (XXM); 3. 
XX female with ovaries (XXF); and 4. XY female with ovaries (XYF). Independent 
effects of the sex hormones can be evaluated by comparing XXF and XXM mice or 
XYM and XXM mice without the confounding issue of the sex/gonadal hormones 
[45]. Similarly, in the comparisons of XXF vs. XYF or XYM vs. XFM, one can evalu-
ate independent effects of the sex chromosomes.
By taking advantage of the FCG mice, we showed that, independent of the sex 
hormones, the sex chromosomes had a sex-biasing effect on BC development [46]. 
We further showed that regardless of gonadal sex XY mice had 2.55 times of higher 
chance of developing BBN-induced BC than XX mice, demonstrating an indepen-
dent role of the sex chromosomes. This study has also confirmed the sex-biasing 
role of androgens and further revealed that having testes was 4.71 times more likely 
than having ovaries to develop BC. More strikingly, wild type male mice with the 
XY chromosome complement and testes were 12.39 times more likely than wild type 
female mice with the XX chromosome complement and ovaries. This is unexpected 
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because it is close to the product of 2.55 and 4.71 instead of the sum. Such finding 
suggests that both the sex chromosomes and the sex hormones have independent 
and dependent sex-biasing effects on BC. Moreover, the sex chromosomes interact 
with the sex hormones to amplify the difference (Figure 1). The underlying mecha-
nism of interaction between these sex-biasing factors is yet to be defined.
Because the Y chromosome is frequently lost in BC cells and its loss has been 
associated with a higher cancer risk [47–49], it is less likely that the Y chromosome 
explains the male dominance in BC. A more reasonable possibility is that copy 
number difference of the X chromosome may render females better protected than 
males. To understand the potential tumor suppressing role of the X chromosome, 
we have examined the X chromosome-linked genes that escape X chromosome 
inactivation (XCI) (Figure 1a) [50], hence, genes that are expressed in higher levels 
in XX than in XY urothelial cells. By comparing gene expression levels in the blad-
der urothelium of FCG mice, we have identified Lysine Demethylase 6A (KDM6A) 
Figure 1. 
Major contributing factors of sex differences in bladder cancer. a) Schematic diagram of human sex 
chromosome complement of XX females and XY males. Genes that are reportedly escaped X-chromosome 
inactivation (XCI) in both mouse and human are indicated. PAR, Pseudo Autosomal Regions. b) Somatic 
DNA mutation rate of the candidate XCI escapees in bladder cancer. c) A proposed model that interactions 
among the sex chromosomes, sex hormones, and sex epigenome amplify male and female differences in 
bladder cancer.
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as a top candidate of X-linked tumor suppressors [46]. KDM6A encodes a histone 
demethylase to remove methyl group from methylated histone H3 at lysine K27 to 
allow gene transcription. Somatic loss-of-function mutations of human KDM6A 
are tightly associated with BC, suggesting a tumor suppressive function in humans 
[51–54]. Interestingly, KDM6A mutations have been shown to be more common 
in female patients with non-muscle invasive BC (NMIBC) [54]. We showed that 
after conditional Kdm6a KO in the urothelium of female mice, susceptibility to 
BBN-induced BC was significantly increased. Similarly, down-regulation or muta-
tion of KDM6A was tightly linked to advanced disease stages and poor outcomes 
among female but not male BC patients [46]. Urothelium-specific Kdm6a KO did 
not exhibit apparent phenotype in male mice. A lack of phenotype in males is 
potentially due to the compensatory effect of a paralog gene UTY on the Y chromo-
some, albeit that UTY lacks any detectable demethylase activity in vivo [55–58]. In 
addition to KDM6A, other X-linked genes have also been suggested to contribute to 
sex differences in cancer [59]. While these candidate genes were expressed in higher 
levels in females than in males, their expression was not associated with disease 
outcomes of BC (Figure 1b) [46]. Collectively, these findings suggest that KDM6A 
is a prototypical sex-biasing tumor suppressor in BC.
2.4 The sex epigenome
Through the intrinsic histone demethylase activity, KDM6A regulates down-
stream gene transcription by antagonizing Polycomb Repressive Complex 2 
(PRC2)-dependent epigenetic gene silencing program [60–63]. Specifically, 
KDM6A catalyzes removal of the methyl groups from histone H3 lysine 27 tri-
methylation (H3K27me3), making H3K27 available for acetylation (H3K27ac). 
H3K27me3 and H3K27ac are closely associated with transcription repression and 
activation, respectively. In a demethylase-independent manner, KDM6A functions 
in the COMPASS-like protein complex that harbors MLL3/KMT2C and MLL4/
KMT2D lysine methyltransferases [64]. KMT2C and KMT2D catalyze formation of 
H3K4 monomethylation (H3K4me1), which is tightly linked to active transcription 
enhancers [65–67]. COMPASS and PRC2 display an antagonistic relationship in 
regulating downstream gene expression [68, 69]. Therefore, KDM6A plays a central 
role in shaping the epigenetic landscape by modulating the PRC2-dependent gene 
silencing and the COMPASS-dependent gene activation. Nearly 74% of NMIBC 
and 23% MIBC patients have mutations in KDM6A [51, 54]. About 18% and 28% of 
human BC patients have somatic mutations in KMT2C and KMT2D, respectively 
[51]. The sex-biased expression of KDM6A suggests that there is an epigenetic dif-
ference in bladder urothelium between sexes, hence the sex epigenome. It is con-
ceivable that KDM6A plays a critical role in creating an epigenetic barrier to prevent 
malignant transformation. Females with more KDM6A may have a tougher barrier 
than males to overcome, thereby are less likely to develop BC.
Whole-genome transcriptome analysis of Kdm6a knockout urothelium indi-
cates that the p53 tumor suppressor pathway is among the top affected pathways 
[46]. The canonical p53 downstream gene targets, Cdkn1a and Perp, which induce 
cell cycle arrest and apoptosis, respectively, are down-regulated significantly in 
KDM6A knockouts. UM-UC-13, a human BC cell line, lacks functional KDM6A due 
to genomic mutation [70]. Expression of wild type KDM6A induces both CDKN1A 
and PERP in UM-UC-13 cells while expression of the catalytically-dead form of 
KDM6A only induces PERP but not CDKN1A, suggesting that KDM6A regulates 
PERP gene expression in a demethylase-independent manner. While persistent 
expression of the enzymatically-dead form of KDM6A is required to suppress 
UM-UC-13 cell proliferation, a transient expression of KDM6A is sufficient to 
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achieve the same result, implying that the demethylase activity of KDM6A results 
in a lasting protective activity or an epigenetic memory of tumor suppression [46]. 
In supporting this notion, Ler et al. revealed that KDM6A mutant BC cells are 
more vulnerable to the pharmacological inhibition of PRC2 [52]. While the precise 
mechanism of KDM6A-dependent tumor suppression remains to be fully eluci-
dated, we suspect that systematic profiling of the sex epigenome would shed new 
light on the gender disparities in BC (Figure 1c).
3. Conclusion
A new concept of sex epigenome begins to emerge. In addition to gonadal 
hormones, the copy number difference of the X chromosome between males and 
females contributes to sex differences in BC - an extra copy of the X chromosome 
confers a better protection of females. Moreover, there is a cooperative interaction 
between the sex hormones and chromosomes during BC development. The tumor 
suppressing effect of the X chromosome is largely mediated by KDM6A-dependent 
epigenetic program, or the sex epigenome. The sex chromosome, sex chromosome, 
and sex epigenome collectively contribute to sex differences in BC.
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